Drug Trial Radar · NCT06500702
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Dec 19, 2024
Primary completion
Dec 23, 2026
Study completion Feb 16, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig or rilzabrutinib compared with placebo in participants with primary FSGS or MCD aged 16 to 75 years. Study details for each participant include: The study duration will be up to 52 weeks. The treatment duration will be 24 weeks. There will be up to 16 visits.
Conditions
- Focal Segmental Glomerulosclerosis
- Glomerulonephritis Minimal Lesion
Interventions
frexalimabDrug
frexalimab treatment
brivekimigDrug
brivekimig treatment
rilzabrutinibDrug
rilzabrutinib treatment
placeboDrug
placebo treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent reduction in urine protein to creatinine ratio (UPCR)Time frame: From baseline to Week 12
Locations
82 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama -The Kirklin Clinic- Site Number : 8400007
Birmingham, Alabama · Recruiting
University of California Irvine Medical Center- Site Number : 8400015
Orange, California · Recruiting
University of California San Francisco - Parnassus Heights- Site Number : 8400012
San Francisco, California · Recruiting
University Of South Florida - Parent- Site Number : 8400025
Tampa, Florida · Recruiting
Emory Children's Center- Site Number : 8400020
Atlanta, Georgia · Recruiting
Northwestern Memorial Hospital- Site Number : 8400014
Chicago, Illinois · Recruiting
Nephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale- Site Number : 8400017
Hinsdale, Illinois · Recruiting
University of Michigan Health System - Ann Arbor- Site Number : 8400010
Ann Arbor, Michigan · Recruiting
InterMed Consultants - Edina Clinic- Site Number : 8400019
Edina, Minnesota · Recruiting
DaVita Clinical Research - Las Vegas - North Rainbow Boulevard- Site Number : 8400018
Las Vegas, Nevada · Active not recruiting
Renal Medicine Associates- Site Number : 8400028
Albuquerque, New Mexico · Recruiting
Columbia University Irving Medical Center- Site Number : 8400001
New York, New York · Recruiting
The Children's Hospital at Montefiore- Site Number : 8400027
The Bronx, New York · Recruiting
UNC Kidney Center- Site Number : 8400021
Chapel Hill, North Carolina · Recruiting
Cleveland Clinic - Cleveland- Site Number : 8400029
Cleveland, Ohio · Recruiting
Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400024
Dallas, Texas · Recruiting
El Paso Kidney Specialists- Site Number : 8400005
El Paso, Texas · Recruiting
Prolato Clinical Research Center- Site Number : 8400016
Houston, Texas · Recruiting
Investigational Site Number : 0320001
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320002
Córdoba, Argentina · Recruiting
Investigational Site Number : 0360003
Garran, Australian Capital Territory, Australia · Recruiting
Investigational Site Number : 0360001
Parkville, Victoria, Australia · Recruiting
Hospital do Rim e Hipertensão- Site Number : 0760002
São Paulo, Brazil · Recruiting
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760001
São Paulo, Brazil · Recruiting
Universidade Estadual Paulista - Faculdade de Medicina de Botucatu- Site Number : 0760004
Botucatu, São Paulo, Brazil · Recruiting
Synvia Clinical- Site Number : 0760005
São Paulo, São Paulo, Brazil · Recruiting
Investigational Site Number : 1240002
London, Ontario, Canada · Recruiting
Investigational Site Number : 1240004
Toronto, Ontario, Canada · Recruiting
Investigational Site Number : 1240001
Montreal, Quebec, Canada · Recruiting
Investigational Site Number : 1240005
Montreal, Quebec, Canada · Recruiting
Investigational Site Number : 1240006
Québec, Quebec, Canada · Recruiting
Investigational Site Number : 1520003
Temuco, La Araucanía, Chile · Recruiting
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1560001
Beijing, China · Recruiting
Investigational Site Number : 1560003
Chengdu, China · Recruiting
Investigational Site Number : 1560004
Shanghai, China · Completed
Investigational Site Number : 2030002
Olomouc, Czechia · Recruiting
Investigational Site Number : 2030001
Prague, Czechia · Recruiting
Investigational Site Number : 2500002
Créteil, France · Recruiting
Investigational Site Number : 2500001
Paris, France · Recruiting
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.